Industries
Precision Medicine
Precision medicine applies molecular profiling—genomics, transcriptomics, proteomics, and metabolomics—to tailor medical interventions to individual patients rather than population averages. Companies such as Foundation Medicine, Guardant Health, Tempus AI, and Illumina supply the next-generation sequencing panels, bioinformatics pipelines, and clinical-grade reporting systems that oncologists rely on to match tumors with targeted therapies. Scientists procure tissue- and liquid-biopsy panels, gene-expression classifiers, pharmacogenomics assays, and data-integration platforms that aggregate multi-omic measurements with electronic health records. The FDA Breakthrough Device Designation pathway has accelerated companion-diagnostic launches, while real-world evidence frameworks from the EMA and Asian health authorities are expanding reimbursement. Research teams purchasing for large-scale biobanks, clinical trial sites, or hospital genomics laboratories evaluate sequencing throughput, turnaround time, variant-calling accuracy, and bioinformatics interoperability when selecting vendor platforms.
Details
- Companies
- Foundation MedicineGuardant HealthTempus AIIlluminaVeracytePersonalisMyriad Genetics
- Market Size
- $88 billion (2024), projected $216 billion by 2030 at 16.2% CAGR
- Target Researchers
- Clinical researchers, oncologists, genomicists, biomarker scientists, pharmacogenomicists, and translational medicine teams developing patient-stratified treatment approaches.
- Use Cases
- Genomic tumor profiling for oncology treatment selectionPharmacogenomics testing and drug-dose optimizationRare disease molecular diagnosisBiomarker-driven clinical trial designCompanion diagnostics co-developmentPopulation-scale genomic biobankingLiquid biopsy circulating tumor DNA monitoring